CTLA4 and neoplasm: Checkpoint inhibitors targeting receptors expressed on tumor-infiltrating T cells, such as PD-1 and CTLA-4, have revolutionized immuno-oncology, resulting in durable clinical remissions in a subset of patients across multiple cancer indications.